Skip to content

Anti-obesity effect of Pu-erh tea drinking in obese parameters (bodyweight and body fat).

Effect of Pu-erh tea in the obese parameters of overweight participants: double-blind, randomized controlled trial - Effect of Pu-erh tea in the obese parameters of overweight participants

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000053941
Enrollment
70
Registered
2024-03-25
Start date
2024-03-25
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adults

Interventions

Duration: 12 weeks Test drink: Pu-erh tea Directions and administration: Three times a day, take 200mL of Pu-erh tea bags extracted with boiling water for 3 minutes. Duration: 12 weeks Test food:

Sponsors

University of Shizuoka
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Healthy adult aged 30 to 65 with a BMI of 25 to 30

Exclusion criteria

Exclusion criteria: 1)Subjects who are pregnant or lactating 2)Subjects with a history of stroke, heart disease, or chronic kidney disease 3)Subjects taking antidiabetic drugs, dyslipidemia drugs, hyperuricemia, gout drugs, or antihypertensive drugs 4)Subjects who have developed allergic symptoms to green tea, oolong tea, black tea, Pu-erh tea, barley tea (wheat), etc. 5)Subjects who have not participated in another clinical trial aimed at weight loss for less than 3 months 6)Subjects who are judged as unsuitable for the study by the investigator for the other reason

Design outcomes

Primary

MeasureTime frame
Change of percent body fat after 12-weeks of administration.

Secondary

MeasureTime frame
Change in body weight, waist circumference, serum triglyceride, serum total cholesterol levels.

Countries

Japan

Contacts

Public ContactYuki Shimba

University of Shizuoka Assistant Professor School of Food and Nutritional Sciences

shokuji@u-shizuoka-ken.ac.jp054-264-5561

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026